Targeting cancer stem cells (CSCs) in the gut comes with the challenge that following ablation of LGR5+ CSCs, LGR5- cells have the potential to de-differentiate to CSCs (Morgan et al., 2018). This evidence concerns the gene LGR5 and cancer.